IP Library Granted Patent US 10,426,744
Granted Patent B2
US 10,426,744 · App. 16/026,542 · Granted Oct 1, 2019

Anti-fungal compositions for treating nails and methods for fabricating and using thereof

Inventor: Dennis Elias Saadeh (Irvine, CA)
Assignee: Harrow Health, Inc.
A61K31/137A61K9/06A61K31/192A61K31/4174A61K31/4196A61K47/10A61K47/12A61K47/40A61P31/10A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,426,744
App. No.
16/026,542
Granted
Oct 1, 2019
Kind
B2
Abstract

Pharmaceutical compositions for treating, mitigating or preventing fungal nail diseases, disorders or pathologies are described, the compositions comprising at least one functionalized allylamine compound, at least one functionalized triazole compound, and at least one functionalized imidazole compound. Methods for fabricating the compositions and using them are also described.

Claims (22)

1. A pharmaceutical composition for treating, mitigating or preventing fungal nail diseases, disorders or pathologies, the composition consisting of:

(a) a therapeutically effective quantity of an antifungal component consisting of:

(a1) at least one functionalized allylamine compound;

(a2) at least one functionalized triazole compound; and

(a3) at least one functionalized imidazole compound;

(b) a therapeutically effective quantity of at least one pharmaceutically acceptable penetration enhancing compound selected from the group consisting of ibuprofen and β-cyclodextrin; and

(c) at least one pharmaceutically acceptable excipient that is compatible with the antifungal component and the penetration enhancing compound, wherein the pharmaceutically acceptable excipient is selected from group consisting of glycol and benzyl alcohol,

wherein the composition has a pH in a range between about 2.0 and 6.5, and wherein the composition is formulated in a form that is suitable for topical administration.

2. The composition of claim 1 , wherein the functionalized allylamine compound is selected from the group consisting of terbinafine, amorolfin, butenafine, flunarizine naftifine, and pharmaceutically suitable salts or hydrates thereof.

3. The composition of claim 2 , wherein the functionalized allylamine compound is terbinafine.

4. The composition of claim 1 , wherein the functionalized triazole compound is selected from the group consisting of fluconazole, isavuconazole, itraconazole, terconazole, voriconazole, albaconazole, efinaconazole, epoxiconazole, propiconazole, ravuconazole, posaconazole, and pharmaceutically suitable salts or hydrates thereof.

5. The composition of claim 4 , wherein the functionalized triazole compound is fluconazole.

6. The composition of claim 1 , wherein the functionalized imidazole compound is selected from the group consisting of miconazole, ketoconazole, clotrimazole, sertaconazole, sulconazole, tioconazole, fenticonazole, isoconazole, bifonazole, econazole, omoconazole, luliconazole, butoconazole, oxiconazole, and pharmaceutically suitable salts or hydrates thereof.

7. The composition of claim 6 , wherein the functionalized imidazole compound is miconazole.

8. The composition of claim 1 , wherein the antifungal component consists of terbinafine, fluconazole, and miconazole.

9. The composition of claim 1 , wherein the glycol is propylene glycol.

10. The composition of claim 1 , wherein the composition is in the form of a topical cream, a gel or an ointment.

11. The composition of claim 1 , wherein the composition has a pH of about 2.5 to 5.5.

12. The composition of claim 11 , wherein the composition has a pH of about 3.0 to 4.0.

13. The composition of claim 12 , wherein the composition has a pH of about 4.0.

14. The composition of claim 8 , wherein the composition has a pH of about 4.0.

15. A kit, comprising the pharmaceutical composition of claim 1 , a container for housing the pharmaceutical composition, a delivery device, and instructions for use.

Assignments (8)
SECURITY INTEREST Recorded Sep 26, 2025
From: HARROW, INC.; HARROW IP, LLC
To: FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 072384/0781 →
RELEASE OF SECURITY INTEREST Recorded Sep 18, 2025
From: OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT
To: HARROW IP, LLC
Reel/Frame 072299/0911 →
PATENT SECURITY AGREEMENT Recorded Mar 30, 2023
From: HARROW IP, LLC
To: OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 063205/0708 →
RELEASE OF SECURITY INTEREST Recorded May 7, 2021
From: SWK FUNDING LLC
To: HARROW IP, LLC
Reel/Frame 056174/0332 →
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 21, 2019
From: HARROW IP, LLC
To: SWK FUNDING LLC, AS COLLATERAL AGENT
Reel/Frame 051079/0453 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2019
From: HARROW HEALTH, INC.
To: HARROW IP, LLC
Reel/Frame 050903/0404 →
CHANGE OF NAME Recorded Jan 4, 2019
From: IMPRIMIS PHARMACEUTICALS, INC.
To: HARROW HEALTH, INC.
Reel/Frame 048013/0368 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2018
From: SAADEH, DENNIS ELIAS
To: IMPRIMIS PHARMACEUTICALS, INC.
Reel/Frame 047086/0243 →